Format

Send to

Choose Destination
Biosci Rep. 2018 Nov 20;38(6). pii: BSR20181384. doi: 10.1042/BSR20181384. Print 2018 Dec 21.

Rhotekin 2 silencing inhibits proliferation and induces apoptosis in human osteosarcoma cells.

Author information

1
Department of Orthopedics, The First Hospital of Lanzhou University, Lanzhou 730000, China.
2
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
3
Department of Orthopedics, Guangzhou Huaxin Orthopedic Hospital, Guangzhou, China.
4
Division of Rheumatology, Penn State Hershey College of Medicine, Hershey, PA, U.S.A.
5
First Clinical Medical College, Lanzhou University, Lanzhou, China.
6
Department of Orthopedics, The First Hospital of Lanzhou University, Lanzhou 730000, China ypwangmd@163.com.

Abstract

Human osteosarcoma is the most frequent primary malignant of bone, and often occurs in adolescents. However, molecular mechanism of this disease remains unclear. In the present study, we found that the level of Rhotekin 2 (RTKN2) was up-regulated in osteosarcoma tissues and cell lines. In addition, silencing of RTKN2 of human osteosarcoma cell lines U2OS, inhibited proliferation, and induced G1 phase cell cycle arrest via reducing the level of the cyclin-dependent kinase 2 (CDK2). Furthermore, RTKN2 knockdown in the U2OS cells induced apoptosis by increasing the level of Bax and decreasing the level of Bcl2. These results suggested that RTKN2 is involved in the progression of human osteosarcoma, and may be a potential therapeutic target.

KEYWORDS:

RTKN2; apoptosis; cell cycle; osteosarcoma; proliferation

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center